Active Biotech: Active Biotech AB Interim report January - June 2016

      
Laquinimod

• The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
• The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
• Positive results concerning laquinimod were presented at the 68th AAN Annual Meeting (American Academy of Neurology), held in Vancouver, Canada, on April 15-21, 2016

Tasquinimod     

• The complete study results of the Phase 3 10TASQ10 study have been published in the Journal of Clinical Oncology
• Out-licensing activities are continuing

ANYARA, Paquinimod (57-57) and SILC (ISI)

• Out-licensing activities are continuing

Financial summary

SEK M	  Q2		   Q1-Q2		Full Year
Â	2016	2015	2016	2015	2015
Â	Â	Â	Â	Â	Â
Net sales	3.9	3.2	7.9	6.1	16.3
Operating loss	-14.5	-70.1	-30.6	-127.5	-177.9
Loss for the period	-15.5	-71.4	-32.3	-129.3	-193.5
Loss per share, before and after dilution (SEK)	-0.17	-0.79	-0.36	-1.44	-2.15
Cash and cash equivalents (at the end of the period)	Â	Â	57.4	186.6	103.6

• Refocusing of the company is completed, operating costs reduced by 71% (SEK 95.2 M) compared with 2015
   
• The number of employees will be reduced from 56 (June 2015) to 17 by the end of the third quarter of 2016
   
• Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

  Tomas Leanderson, President and CEO   Tel: [phone]     Hans Kolam, CFO   Tel: [phone] Â

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: [phone] Fax: [phone] Â

The report is also available at www.activebiotech.com (http://www.activebiotech.com).

Active Biotech AB (publ) Interim Report January - June 2016 (http://hugin.info/1002/R/2034058/757619.pdf)

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

HUG#2034058